// Current news

EcoVadis is an independent platform for CSR reviews, on which companies can register the measures they take to implement corporate responsibility and have them reviewed.

“We are pleased by the positive recognition of our efforts to demonstrate sustainability and are motivated and committed to improve further” emphasizes Dr. Lutz Thomas, CEO of AMINO GmbH, the company’s future goals.

Great news for AMINO: The state of Lower Saxony, the Federal Government and the European Regional Development Fund have decided to grant financial support in the amount of EUR 1.8 Mio for the expansion of the company’s operational infrastructure and its utilities.

The Investment and Development Bank of Lower Saxony (NBank) thereby rewards the company’s commitment to invest into its facilities in Frellstedt in the district of Helmstedt. Within the next years AMINO plans to make an investment of EUR 9 Mio targeted at the construction of a research & development centre and the modernization of the site’s utilities infrastructure. The goal of the company is - according to Managing Director Dr. Lutz Thomas - to further increase the innovative power of the company and to strengthen the operations for the future.

AMINO and Hufort Healthcare Pvt. Ltd. have entered a new cooperation by signing a distribution and agency agreement.

Hufort, headquartered in Mumbay (India), specializes in the distribution and registration of active pharmaceutical ingredients. Hufort shall market, sell and distribute APIs manufactured by AMINO to Indian pharmaceutical customers.
“Working with Hufort Healthcare we allow us to access the Indian market, which holds an enormous potential for our company” says Dr. Shahid Iqbal Awan – the regional sales representative.

The AMINO GmbH was awarded by the German Stifterverband with the certificate “Innovative through Research” for its research and development activities. The association collects regularly R & D data in order to identify the innovation power of German companies in order to develop appropriate development programs. “Our AminoVation-team develops new products and sustainable processes for the company.” explains Dr. Lutz Thomas, CEO of AMINO GmbH. “As an innovative company we are happy about the appreciation.”

Together with its distribution partner IMCoPharma (Bílovec, Czech Republic) AMINO has successfully registered amino acids with the Ukrainian ministry for health.

The registration in Kiev enables AMINO to sell the amino acids in the Ukraine for pharmaceutical applications.
Dr. Lutz Thomas, CEO of AMINO, is pleased about the successful registration of the products and states: “Our strategy involves the international expansion of our target markets and this marks a big step in the right direction. Furthermore this strengthens our relationship with IMCoPharma.”

AMINO offers L-histidine based on non-animal raw materials.

The existing portfolio of fermentation products is consequently upgraded by L-histidine. “This addition to our product range steadily strengthens our business portfolio and we are just a few steps away from completing the range of amino acids from our own production“, comments Dr. Lutz Thomas, Managing Director of AMINO GmbH.

The semi-essential amino acid L-histidine possesses, thanks to the imidazole ring, aromatic properties whose central role in enzyme catalysis is of metabolic importance. As a component of hemoglobin L-histidine is responsible for the formation of red blood cells and therefore for the support of oxygen transport. In pharmaceutical applications, L-histidine is e.g. used as a component for infusion solutions. Because of L-histidine primarily having to be feed to infants, it is widely used in infant formula and in dietetic products.

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-tyrosine from fermentation by the European Directorate for the Quality of Medicines (EDQM).

AMINO is pleased that the certification of tyrosine derived from a fermentative manufacturing process expands the product portfolio of semi-essential amino acids. „The growth of our range for amino acids by tyrosine is an important step towards our growth plans” comments Dr. Lutz Thomas, Managing Director of AMINO GmbH.

With that authorization it is possible for AMINO, that focuses on the safe and effective production of pharmaceutical and nutritional substances, to expand the product portfolio at the amino acid market, especially for tyrosine and its derivatives.

AMINO has been granted a Certificate of Suitability (CEP) for the production of L-histidine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased to expand our portfolio for regulated pharmaceutical applications”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “Histidine is one of the increasingly important amino acid of our broad product spectrum, hence we are very pleased that it is now CEP certified”, adds Dr. Lutz Thomas, Managing Director of AMINO GmbH.

L-histidine is a semi-essential amino acid and is used in many pharmaceutical products and infant formula.

At the same time as the opening of the new Innovation Centre, the AMINO brand was sharpened and refined as part of a new communication strategy.

The modern logo symbolically combines the values of the company with the function of amino acids as the building blocks of life.

The six corporate values are thus reflected in the colour scheme of the logo. Each colour symbolises one of these values on which AMINO's self-image is based: Integrity, performance, communication, respect, responsibility and sustainability.

With the construction of a new innovation center AMINO sets the foundation for the next generation of products and services.

“In parallel to our existing business, i.e. the production of pharmaceutical- grade amino acids, we intend to develop amino acid derivatives and other APIs as well as diversify our production technology”, says Roman Erath, project manager of the new innovation center. “Furthermore we offer our customers development resources for joint projects”, explains Kai-Philipp Thomas, head of marketing & sales, the reasons for the strategic investment.

The construction of the research and development center for approximately € 4.2 Mio is partially co-funded by the NBank to support small and medium-sized enterprises. The new facility will provide ideal conditions for the development of technologies currently not available to AMINO, such as chemical synthesis and derivatization in combination with state-of-the-art methods of analysis. At present projects are underway in a laboratory scale. In the future those projects will be up-scaled to a pilot scale and successively transferred into production. The new innovation center creates a motivating environment for young scientific and technical talents to start their professional career.

“The AminoVation-Team is responsible for the design of the new center and organizes its workplace at their own discretion” outlines CEO Dr. Lutz Thomas an additional positive effect for the Company.

The AMINO GmbH reviews a strategic partnership with MH2 Biochemical Co., Ltd (Korea).

The South Korean company, founded in 2003, is a manufacturer of biochemical products focusing on D-amino acids and supplying customers within the health and cosmetic sector. Through a cooperation with MH2 AMINO aims to expand its product offering in order to promote its international growth strategy. “First we have to carry out negotiations with MH2 to see how a cooperation between the two companies could work,” says Dr. Lutz, Thomas, CEO of AMINO.
“In any event we are interested in integrating new products and technologies into our range of products and services.”

AMINO GmbH announces that a new subsidiary was established under the name of Amino Korea Co., Ltd. The registration of Amino Korea was executed and authorized in Seoul as of July 4, 2018. "Through this subsidiary, we aim to expand our pharmaceutical-grade amino acids business in Asia by enhancing partnerships with customers and suppliers in a timely and sustainable manner to accelerate our international growth strategy" said Dr. Lutz Thomas, CEO of AMINO GmbH.

AMINO is pleased to announce the foundation of AMixCo Premix GmbH dedicated to entering the market of amino acid premixes.

As a manufacturer of premixes from active pharmaceutical or nutritional ingredients, AMixCo ensures the optimal composition of amino acids in various pharmaceutical and dietetic products.

Under the AMixCo brand amino acid premixes of a high quality and with a high reliability in tailor-made formulations will be offered. Customer-specific packaging and formulation are core competencies that form an integral part of the offer that AmixCo brings to its customers.

"The new positioning of AMixCo means an extension of our products and services repertoire for our customers and builds on the established market and production expertise of Amino GmbH to fulfill the specific requests of our customers," explains Project Manager Alexander Rath.

Please visit our homepage and contact us!

www.amixco.de/en

AMINO received the Gold award and is therefore part of the top five percent of all companies rated by Eco Vadis.

EcoVadis is an independent platform for CSR reviews, on which companies can register the measures they take to implement corporate responsibility and have them reviewed.

“We are pleased with the positive recognition of our efforts to be sustainable and feel motivated and committed to improve further” says Kathrin Ebers, sustainability agent at AMINO GmbH, when asked about the company’s future goals.

AMINO has been granted the Certificate of Suitability (CEP) for the production of L-arginine by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased to expand our portfolio for amino acids from fermentation for regulated pharmaceutical applications by receiving the CEP for L-arginine”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “L-arginine, a semi-essential amino acid, is a mandatory component of pharmaceutical and specialty nutrition products and hence a strategically important addition to our product spectrum”, adds Dr. Lutz Thomas, Managing Director of AMINO GmbH.

Amino has been granted the Certificate of Suitability (CEP) for the production of L-Lysine Acetate by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

“We are pleased that we can now add the first amino acid salt to our product portfolio for regulated pharmaceutical applications.”, states Kai-Philipp Thomas, responsible for Regulatory Affairs at AMINO. “With this step we have succeeded the expansion of our product portfolio by amino acid derivatives.”, adds Michael Marx, Project Manager of the AMINOVATION-Team (www.aminovation.de).

L-Lysine is an essential amino acid, but is because of its poor stability as free base difficult to access for the human body. Therefore in many pharmaceutical and nutritional products the salts of L-lysine are used like L-lysine acetate. Due to the higher stability of L-lysine acetate the bioavailability of L-lysine rises.